ASND · Ascendis Pharma A/S · Metrics
$259.85
+3.03 (+1.18%)
At close · Nov 9
Return incl. dividend (before tax)
Play latest call
Q2 2026 earnings call transcript
Market Cap
$17.10B
Shares
65.80M
Volume · Nov 9
896.06K
Avg daily vol (3M)
709.57K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
ASND metrics
77 of 125 screener metrics currently available.
Market overview
2 metricsShare price
$259.85
Market cap
$17.10B
Price action
23 metricsPrice change (1W)
+4.4%
Price change (30D)
+14.5%
Price change (3M)
+1.7%
Price change (6M)
+8.9%
Price change (YTD)
+21.9%
Price change (1Y)
+31.4%
Trailing year
Price change (5Y)
+63.7%
52-week high
$277.18
52-week low
$196.01
Change from 52-week high
-6.3%
Change from 52-week low
+32.6%
Annualized volatility
38.6%
Annualized volatility (3M)
36.5%
Implied volatility (30D)
47.1%
IV rank (1Y)
34.0
IV percentile (1Y)
52.0
Beta
0.4
RSI (14D)
67.3
Price vs SMA 50
+7.1%
Price vs SMA 200
+8.7%
Avg volume (3M)
709,572
Relative volume
1.3
Average dollar volume
$172.23M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
65.80M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
13.9×
reciprocal yield 7.2%
EV / EBITDA
—
EV / EBIT
54.9×
reciprocal yield 1.8%
P / sales
13.8×
reciprocal yield 7.2%
P / book
10.3
reciprocal yield 9.7%
FCF yield
—
TTM · current market cap
Buyback yield
0.7%
P / FCF
—
P / operating cash flow
41.6
reciprocal yield 2.4%
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.7%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-08-13
Profitability
9 metricsGross margin
91.3%
Operating margin
25.4%
Trailing 12 months
Net margin
70.8%
Gross profit (TTM)
$955.89M
Operating profit (TTM)
$266.17M
Net income (TTM)
$866.82M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
-658.2%
Growth
11 metricsRevenue growth YoY
+114.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.22B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.1%
Year over year · more shares
Revenue CAGR (3Y)
+141.4%
Revenue CAGR (5Y)
+153.0%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
51.6%
Return on assets
32.4%
Debt / equity
—
Current ratio
3.0
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
2.3
Interest coverage
1.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$122.31M
Latest balance sheet
Cash & equivalents
$927.36M
Total assets
$2.61B
Total debt
$845.30M
Cash flow & spend
7 metricsOperating cash flow (TTM)
$406.57M
Capital expenditures (TTM)
$1.02M
R&D (TTM)
$326.49M
SG&A (TTM)
—
Stock compensation (TTM)
$140.63M
R&D / revenue
26.7%
Stock compensation / revenue
11.5%
Ownership (13F)
9 metrics13F filers
317
13F filer change QoQ
+31
Institutional ownership
102.8%
Conviction holders (share of 13F filers)
4.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+3.1%
Holder tenure
18.7
Price vs estimated holder cost
+52.4%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.4%
Short interest
3 metricsShort interest
4.8%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
60 / 100
Insider activity
2 metricsNet insider buying (90D)
−$380,251
Insider-sentiment score
47 / 100
Risk flags
1 metricsGoing concern
—
Key facts
CIK
1612042
CUSIP
K08588103
13F (30d)
151 filings
129 filers
Visit website
Investor relations